pSiVida Corp.

EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference

EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference

WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that George Elston, Chief Financial Officer of EyePoint Pharmaceuticals, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:30 p.m. ET.

A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at . The replay will be available for 90 days after the event.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary erodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit .

Investors:

Christina Tartaglia

Stern IR

Direct: 212-698-8700

Media Contact

Amy Phillips

Green Room Communications

Direct: 412-327-9499



EN
31/05/2023

Underlying

pSiVida Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on pSiVida Corp.

 PRESS RELEASE
Free
PSIVIDA CORP.

EyePoint Provides Company Update and Anticipated Development Milestone...

EyePoint Provides Company Update and Anticipated Development Milestones for 2025 – Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2 VERONA clinical trial of DURAVYU in DME expected in 1Q 2025 – – Appointed renowned retina specialist and industry leader Reginald J. Sanders, M.D., FASRS to Board of Directors – – Cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – – Presenting at the 43rd Annual J.P. Morgan He...

January 13, 2025 1 EN
 PRESS RELEASE
Free
PSIVIDA CORP.

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Regi...

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. “I am pleased to welcome Dr. Sanders to EyePoint’s Board,” said Göran Ando, M.D., Chair of the ...

January 8, 2025 1 EN
 PRESS RELEASE
Free
PSIVIDA CORP.

EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conferen...

EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference WATERTOWN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET. A webcast and subsequent archiv...

December 17, 2024 1 EN
 PRESS RELEASE
Free
PSIVIDA CORP.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listin...

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggreg...

December 16, 2024 1 EN
 PRESS RELEASE
Free
PSIVIDA CORP.

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA ...

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration – Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the LUCIA trial, the Company’s second global Phase 3 clinical trial of DURAV...

December 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch